Limits...
Cancer immunotherapy: Benefit and harm?

Characiejus D - Oncoimmunology (2012)

Bottom Line: In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment immune parameters of a patient.The results described in the article show that immunotherapy may prolong survival in certain subgroups of cancer patients, while in other subgroups a cancer-promoting effect of this treatment modality cannot be excluded.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Medicine; Vilnius University; Vilnius, Lithuania.

ABSTRACT
In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment immune parameters of a patient. The results described in the article show that immunotherapy may prolong survival in certain subgroups of cancer patients, while in other subgroups a cancer-promoting effect of this treatment modality cannot be excluded.

No MeSH data available.


Related in: MedlinePlus

Figure 1. Schematic outline of the implications of the data reviewed in this article. Depending on pre-treatment immune parameters, immunotherapy may prolong survival in one subgroup of patients, while in another subgroup survival may be decreased compared with non-treated patients. As a result, the total effect of the therapeutic intervention may be ified.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3376986&req=5

Figure 1: Figure 1. Schematic outline of the implications of the data reviewed in this article. Depending on pre-treatment immune parameters, immunotherapy may prolong survival in one subgroup of patients, while in another subgroup survival may be decreased compared with non-treated patients. As a result, the total effect of the therapeutic intervention may be ified.

Mentions: In conclusion, our results reviewed in this article and the results by other authors (for a review see ref. 9) strongly suggest that the outcome of immunotherapy depends on pre-treatment immune parameters of a cancer patient. Immunotherapy may prolong survival in certain subgroups of patients, most likely in those with poor immunological prognostic factors. However, immunotherapy should be administered cautiously to patients with good immunological prognostic factors, because a cancer-promoting effect of this treatment modality cannot be excluded (for a review see ref. 7). Schematic outline of the implications of the data reviewed in this article is shown in Figure 1.


Cancer immunotherapy: Benefit and harm?

Characiejus D - Oncoimmunology (2012)

Figure 1. Schematic outline of the implications of the data reviewed in this article. Depending on pre-treatment immune parameters, immunotherapy may prolong survival in one subgroup of patients, while in another subgroup survival may be decreased compared with non-treated patients. As a result, the total effect of the therapeutic intervention may be ified.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3376986&req=5

Figure 1: Figure 1. Schematic outline of the implications of the data reviewed in this article. Depending on pre-treatment immune parameters, immunotherapy may prolong survival in one subgroup of patients, while in another subgroup survival may be decreased compared with non-treated patients. As a result, the total effect of the therapeutic intervention may be ified.
Mentions: In conclusion, our results reviewed in this article and the results by other authors (for a review see ref. 9) strongly suggest that the outcome of immunotherapy depends on pre-treatment immune parameters of a cancer patient. Immunotherapy may prolong survival in certain subgroups of patients, most likely in those with poor immunological prognostic factors. However, immunotherapy should be administered cautiously to patients with good immunological prognostic factors, because a cancer-promoting effect of this treatment modality cannot be excluded (for a review see ref. 7). Schematic outline of the implications of the data reviewed in this article is shown in Figure 1.

Bottom Line: In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment immune parameters of a patient.The results described in the article show that immunotherapy may prolong survival in certain subgroups of cancer patients, while in other subgroups a cancer-promoting effect of this treatment modality cannot be excluded.

View Article: PubMed Central - PubMed

Affiliation: Faculty of Medicine; Vilnius University; Vilnius, Lithuania.

ABSTRACT
In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment immune parameters of a patient. The results described in the article show that immunotherapy may prolong survival in certain subgroups of cancer patients, while in other subgroups a cancer-promoting effect of this treatment modality cannot be excluded.

No MeSH data available.


Related in: MedlinePlus